1.WHO. HIV/AIDS 2018 [cited 2019 29 March]. Available from: https://www.who.int/en/news-room/fact-sheets/detail/hiv-aids.
2.National Center for AIDS/STD Control and Prevention CC. Update on the AIDS/STD epidemic in China in August, 2018. AIDS/STD in China. 2018;24(10):965.
3.Bor J, Herbst AJ, Newell M-L, Bärnighausen T. Increases in Adult Life Expectancy in Rural South Africa: Valuing the Scale-Up of HIV Treatment. Science. 2013;339(6122):961–5.
4.Hocqueloux L, Avettand-Fenoel V, Jacquot S, Legac TP, Me´lard A, Niang M, Mille C, Moal GlL, Viard J-P, Rouzioux C. Long-term antiretroviral therapy initiated during primary HIV–1 infection is key to achieving both low HIV reservoirs and normal T cell counts. J Antimicrob Chemother. 2013;68:1169–78.
5.Viviane D. Lima, Harrigan R, Bangsberg DR, Robert S. Hogg, Gross R, Yip B, Montaner JSG. The Combined Effect of Modern Highly Active Antiretroviral Therapy Regimens and Adherence on Mortality Over Time. J Acquir Immune Defic Syndr. 2009;50(5):529–36.
6.Fofana DB, Soulie C, Balde´ A, Lambert-Niclot S, Sylla M, Ait-Arkoub Z, Diallo F, Sangare B, Cisse M, Maı¨ga IA, et al. High level of HIV–1 resistance in patients failing long-term first-line antiretroviral therapy in Mali. J Antimicrob Chemother. 2014;69(9):2531–5.
7.Esté JA, Cihlar T. Current status and challenges of antiretroviral research and therapy. Antivir Res. 2010;85(1):25–33.
8.Tang MW, Shafer RW. HIV–1 antiretroviral resistance: scientific principles and clinical applications. Drugs. 2012;72(9):e1-e25.
9.Booth CL, Geretti AM. Prevalence and determinants of transmitted antiretroviral drug resistance in HIV–1 infection. J Antimicrob Chemoth. 2007;59(6):1047–56.
10.Lu X, Kang X, Liu Y, Li Y, Chen S, Li J, Cui Z. Surveillance of Transmitted Drug Resistance in HIV–1-Infected Youths Aged 16 to 25 Years, a Decade After Scale-up of Antiretroviral Therapy in Hebei, China. AIDS Res Hum Retrovir. 2017;33(4):359–64.
11.Onywera H, Maman D, Inzaule S, Auma E, Were K, Fredrick H, Owiti P, Opollo V, Jean-Franc, Etard o, et al. Surveillance of HIV–1 pol transmitted drug resistance in acutely and recently infected antiretroviral drug-naive persons in rural western Kenya. PLos One. 2017;12(2):e0171124.
12.Todesco E, Charpentier C, Bertine M, Wirden M, Storto A. Disparities in HIV–1 transmitted drug resistance detected by ultradeep sequencing between men who have sex with men and heterosexual populations. HIV Med. 2017;18(9):696–700.
13.Liao L, Xing H, Shang H, Li J, Zhong P, Cheng H, Li X, Shao Y. The prevalence of transmitted antiretroviral drug resistance in treatment-naive HIV-infected individuals in China. J Acquir Immune Defic Syndr. 2010;53(Suppl 1):S10-S4.
14.ShuaiZhao, Feng Y, Hu J, Li Y, ZhongbaoZuo, JingYan, JingZhang, PiCao, WeiXu, Li F, et al. Prevalence of Transmitted HIV drug resistance in antiretroviral treatment naïve newly diagnosed individuals in China. Sci Rep. 2018;8:12273.
15.Lei Z, Eric P F C, Jun J, Xun Z, Xiaoshan L, Meiqi H, Huamin S, Xiaoyan L, Marelize G, David W, et al. HIV prevalence in China: integration of surveillance data and a systematic review. Lancet Infect Dis. 2013;13(11):955–63.
16.Zhenhua D, Shuangfeng F, Rong L, Xueqing W, Yaying S, Zhijun L, Weihua J, Fang L, Zhen D, Xiaodong W, et al. Consistently high HIV prevalence among men who have sex with men in Chengdu city from 2009 to 2014. Int J STD AIDS. 2016;27(12):1057–62.
17.WANG L, WANG L, Norris J, LI D-m, GUO W, DING Z-w, WANG N. HIV prevalence and influencing factors analysis of sentinel surveillance among men who have sex with men in China, 2003 - 2011. CHINESE MED J-PEKING. 2012;125(11):1857–61.
18.Zeng P, Wang J, Huang Y, Guo X, Li J, Wen G, Yang T, Yun Z, He M, Liu Y, et al. The human immunodeficiency virus–1 genotype diversity and drug resistance mutations profile of volunteer blood donors from Chinese blood centers. Transfusion. 2012;52(5):1041–9.
19.Ronald R, Tremblay M, Soudeyns H, DeStephano L, Yao X-J, Fanning M, Montaner JSG, O’Shaughnessy M, Gelmon K, Tsoukas C, et al. Isolation of drug-resistant variants of HIV–1 from patients on long-term zidovudine therapy. Canadian Zidovudine Multi-Centre Study Group. AIDS. 1989;3(7):411–5.
20.Zhao J, Chen L, Chaillon A, Zheng C, Cai W, Yang Z, Li G, Gan Y, Wang X, Hu Y, et al. The dynamics of the HIV epidemic among men who have sex with men (MSM) from 2005 to 2012 in Shenzhen, China. Sci Rep. 2016;6:28703.
21.Fenga Y, Hea X, Hsia JH, Lia F, Lia X, Wangb Q, Ruana Y, Xinga H, Lamc TT-Y, Pybusc OG, et al. The rapidly expanding CRF01_AE epidemic in China is driven by multiple lineages of HIV–1 viruses introduced in the 1990s. AIDS. 2013;27(11):1793–802.
22.Chen M, Jia MH, Ma YL, Luo HB, Chen HC, Yang CJ, Dai J, Yang L, Dong LJ, Lu R, et al. The changing HIV–1 genetic characteristics and transmitted drug resistance among recently infected population in Yunnan, China. Epidemiol Infect. 2018;146(6):775–81.
23.Shu Z, Chen Y, Abudureyimu A, Li T, Yuan T, Ma J, Li X, Ma X, Jang C, Bao G, et al. Surveillance of HIV–1 drug resistance in Xinjiang: high prevalence of K103N in treatment-naïve individuals. Arch Virol. 2018;163(8):2111–9.
24.Li X, Zang X, Ning C, Feng Y, Xie C, He X, Takebe Y, Sun L, Guo Q, Xing H, et al. Molecular Epidemiology of HIV–1 in Jilin Province, Northeastern China: Emergence of a New CRF07_BC Transmission Cluster and Intersubtype Recombinants. PLos One. 2014;30(9):e110738.
25.Li X, Xue Y, Cheng H, Lin Y, Zhou L, Ning Z, Wang X, Yu X, Zhang W, Shen F, et al. HIV–1 Genetic Diversity and Its Impact on Baseline CD4+T Cells and Viral Loads among Recently Infected Men Who Have Sex with Men in Shanghai, China. PLos One. 2015;10(6):e0129559.
26.Ruan Y, Qin G, Liu S, Qian H, Zhang L, Zhou F, He Y, Chen K, Yin L, Chen X, et al. HIV Incidence and Factors Contributed to Retention in a 12-Month Follow-up Study of Injection Drug Users in Sichuan Province, China. J Acquir Immune Defic Syndr. 2005;39(4):459–63.
27.Han X, An M, Zhang W, Cai W, Chen X, Takebe Y, Shang H. Genome Sequences of a Novel HIV–1 Circulating Recombinant Form, CRF55_01B, Identified in China. Genome Announcements. 2013;1(1):1395.
28.Gui T, Zhao J, Sun C, Chen L, Liu Y, Zheng C, Li H, Li T, Bao Z, Wang X, et al. Genetic Characterization of a Unique Recombinant Originating from CRF55_01B, CRF01_AE, and CRF07_BC in Shenzhen, China. AIDS Res Hum Retrovir. 2015;31(5):559–63.
29.Dan Y, Li Y, Ling S, Hong Y, Ying-juan L, Jun H, Dong-bing W, Geng-sheng Z, Shu L, Jia Y, et al. Analysis of the drug resistance and subtype of HIV–1 in patients receiving highly active antiretroviral therapy in Sichuan Province in 2011. Modern Preventive Medicine. 2013;40(22):4248–51.
30.Zhou Y, Lu J, JingeWang, Yan H, Li J, Xu X, Zhang Z, Qiu T, Ding P, Fu G, et al. Prevalence of HIV Antiretroviral Drug Resistance and Its Impacts on HIV–1 Virological Failures in Jiangsu, China: A Cross-Sectional Study. Biomed Res Int. 2016;2016:1752437.
31.Zeng P, Liu Y, He M, Gao Z, Zhou Y, Bian G, Shan H, Wang J. HIV–1 genotypic diversity and prevalence of drug resistance among treatment naive HIV-infected individuals in Chengdu of China. Virus Genes. 2013;47:408–13.
32.Gagliardo C, Brozovich A, Birnbaum J, Radix A, Foca M, Nelson J, Saiman L, Yin M, Carras-Terzian E, West E. A Multicenter Study of Initiation of Antiretroviral Therapy and Transmitted Drug Resistance in Antiretroviral-Naive Adolescents and Young Adults With HIV in New York City. Clin Infect Dis. 2014;58(6):865–72.
33.Fogel JM, Hudelson SE, Ou S-SM, Hart S, Wallis C, Morgado MG, Saravanan S, Tripathy S, Hovind L, Piwowar-Manning. HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results From the HIV Prevention Trials Network 052 Trial. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2016;72(3):304–9.
34.Larder B, Kemp S, Harrigan P. Potential Mechanism for Sustained Antiretroviral Efficacy of AZT–3TC Combination Therapy. Science. 1995;269(5224):696–9.
35.Ross L, Parkin N, Chappey C, Fisher R, Clair M, Bates M, Tisdale M, Lanier E. Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance. AIDS. 2004;18(12):1691–6.
36.Charpentier C, Eholié S, Anglaret X, Bertine M, Rouzioux C, Avettand-Fenoël V, Messou E, Ming A, Damond F, Plantier J-C, et al. Genotypic resistance profiles of HIV–2-treated patients in West Africa. AIDS. 2014;28(8):1161–9.